Idaverine

Idaverine

SCHEMBL180957

CCN(CCCC(=O)N1CCC(C(=O)N(C)C)CC1)[C@@H](C)Cc1ccc(OC)cc1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.46
CYP3A4 P08684 2/20 0.46
ADRB2 P07550 1/20 0.46
HTR1A P08908 1/20 0.46
ADRA2A P08913 1/20 0.46
CYP2D6 P10635 1/20 0.46
CHRM1 P11229 1/20 0.46
DRD2 P14416 1/20 0.46
ADRA2B P18089 1/20 0.46
ADRA2C P18825 1/20 0.46
CHRM3 P20309 1/20 0.46
SLC6A2 P23975 1/20 0.46
HTR2A P28223 1/20 0.46
SLC6A4 P31645 1/20 0.46
DRD3 P35462 1/20 0.46
OPRK1 P41145 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KCNH2 Q12809 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Idaverine SCHEMBL7286939 1.00 TSHR (0.46) TSHRCYP3A4ADRB2HTR1AADRA2A
Idaverine SCHEMBL10340527 0.99 CYP3A4 (0.47) TSHRCYP3A4ADRB2HTR1AADRA2A
SCHEMBL10868814 0.93 TSHR (0.45) TSHRCYP3A4ADRB2HTR1AADRA2A
SCHEMBL10483403 0.93 CYP3A4 (0.46) TSHRCYP3A4ADRB2HTR1AADRA2A
SCHEMBL10483413 0.91 TSHR (0.45) TSHRCYP3A4ADRB2HTR1AADRA2A
SCHEMBL10483315 0.91 TSHR (0.47) TSHRCYP3A4ADRB2HTR1AADRA2A
SCHEMBL10483532 0.90 TSHR (0.51) TSHRCYP3A4ADRB2HTR1AADRA2A
SCHEMBL10483436 0.90 OPRD1 (0.35) TSHRCYP3A4ADRB2HTR1AADRA2A
SCHEMBL10483439 0.90 OPRD1 (0.35) TSHRCYP3A4ADRB2HTR1AADRA2A
SCHEMBL10483450 0.89 HRH3 (0.39) TSHRCYP3A4ADRB2HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116368243-A Replication stress pathway agent compositions and methods for treating cancer 无界生物公司 2023-06-30 CN claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
EP-2305314-A2 Remodelling and glycoconjugation of antibodies BioGeneriX AG (DE) 2011-04-06 EP claimed
EP-2292271-A2 Remodelling and glycoconjugation of an antibody BioGeneriX AG (DE) 2011-03-09 EP claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
CN-122029161-A Crystalline forms of PI3K inhibitors and uses thereof 蝎子疗法股份有限公司 2026-05-12 CN disclosed
EP-4626492-A1 MATRICES FOR WOUND HEALING Regenics AS (NO) 2025-10-08 EP disclosed
EP-3866818-B1 USE OF FISH EGG CELLULAR EXTRACTT FOR WOUND HEALING REGENICS AS (NO) 2025-07-23 EP disclosed
CN-118459413-A Compositions and methods for treating cancer 加利福尼亚大学董事会 2024-08-09 CN disclosed
WO-2024116120-A1 MATRICES FOR WOUND HEALING REGENICS AS (NO) 2024-06-06 WO disclosed
WO-1993007902-A1 ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS RICHARDSON-VICKS, INC. (US) 1993-04-29 WO disclosed
WO-1993007903-A1 ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS RICHARDSON-VICKS, INC. (US) 1993-04-29 WO disclosed
EP-0351897-A2 Skin penetration system for salts of amine-functional drugs THE PROCTER & GAMBLE COMPANY (US) 1990-01-24 EP disclosed
US-4889849-A GASTROINTESTINAL, UROGENITAL, AND RESPIRATORY DISORDERS; SIDE EFFECT REDUCTION DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1989-12-26 US disclosed
EP-0177078-A1 Spasmolytically active tertiary amine derivatives and method of preparing the same DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1986-04-09 EP disclosed